CTIS2023-505225-13-00进行中（未招募）1 期
Single-arm, open label, multicenter clinical study to evaluate the handling and safety of AVT06 pre-filled syringe (PFS) in subjects with chorioretinal vascular disease followed by an optional extension phase of AVT06 pre-filled syringe (PFS). - AVT06-GL-D01
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Male or female =18 years old., Subjects with diagnosis of nAMD (wet), DME, RVO, DR, or myopic CNV in the study eye, treatment naïve or already on aflibercept treatment or its marketed biosimilar., Study eye, eligible for the treatment of aflibercept, will be selected by the Principal Investigator., Subject or his/her legal representative, must be able to read, understand and sign an Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved informed consent form (ICF) before any study-specific procedures., Willing and able to comply with all study procedures and be likely to complete the study., Subjects must be able to follow the contraception requirements as defined: • A male subject must agree to use contraception during the treatment period and for at least 3 months after the last Intravitreal(ly) (IVT) injection of study treatment and refrain from donating sperm during this period. • A female subject is eligible to participate if she is not pregnant (see Appendix 6), not breastfeeding, not intending to become pregnant during the treatment period and for at least 3 months after the last IVT injection of study treatment, and refrains to donate eggs (ova, oocytes) or freeze/store eggs for the purpose of reproduction during this period. The subject should meet at least 1 of the following conditions applies: i) Not a woman of childbearing potential (WOCBP). OR ii) A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 3 months after the last IVT injection of study treatment.
排除标准
- •Evidence of active infections such as but not limited to blepharitis, keratitis, or conjunctivitis in either eye., Subjects with best-corrected visual acuity (BCVA) of <20/200 (<34 letters) as assessed by early treatment diabetic retinopathy study (ETDRS) letter score in both eyes at Screening and Baseline visits., Treatment with any IVT injection in the study eye within 28 days prior to Baseline., Previous therapeutic radiation in the study eye., Any intraocular surgery in the study eye at any time during the past 3 months prior to Baseline., Any prior extended-release therapeutic agent, or ocular drug-release device implantation (approved or investigational including steroids) in the study eye., Any concurrent ocular condition in the study eye which, in the opinion of the Principal Investigator, could either increase the risk to the subject beyond what is to be expected from standard procedures of IVT injections, or which otherwise may interfere with the injection procedure or with evaluation of safety., Active or suspected ocular or periocular infection, within 2 weeks prior to Baseline in either eye., Active scleritis or episcleritis or presence of scleromalacia in either eye., Any macular hole, presence or history of retinal detachment, retinal pigment epithelial tear, and probably neovascular glaucoma in either eye., Previously treated with AVT06 and/or any other anti-VEGF treatment (administered either on the study eye or fellow eye and/or systemic) with the exception of aflibercept or its marketed biosimilar., Any active intraocular inflammation or infection in either eye or history of intraocular inflammation or infection after past IVT injections with any agent in either eye., History of or any current indication of excessive bleeding and recurrent hemorrhages, including any prior excessive intraocular (including subconjunctival) bleeding or hemorrhages after IVT injection or intraocular procedures in either eye., Uncontrolled ocular hypertension (defined as intraocular pressure [IOP] =25 mmHg despite treatment with most antiglaucoma treatment tolerable) at Screening and Baseline visits in either eye.
研究者
相似试验
招募中
1 期
Open-label single-arm, multicenter clinical trial to evaluate patient acceptability of a new CREON formulation of Pancreas Powder gastro-resistant pellets in patients with cystic fibrosis suffering from pancreatic exocrine insufficiency.patients with cystic fibrosis suffering from pancreatic exocrine insufficiencyMedDRA version: 21.0Level: PTClassification code: 10079428Term: Cystic fibrosis gastrointestinal disease Class: 100000004850CTIS2023-503256-27-00MEDA Pharma GmbH & Co. KG80
进行中（未招募）
1 期
ong-term safety and tolerability study of 0.5 mg fingolimod once daily in patients with relapsing forms of multiple sclerosisMedDRA version: 18.0Level: PTClassification code 10048393Term: Multiple sclerosis relapseSystem Organ Class: 10029205 - Nervous system disordersmultiple sclerosisEUCTR2010-020515-37-IEovartis Pharma Services AG5,000
已完成
3 期
A single arm, open-label, multicenter study evaluating the long-term safety and tolerability of 0.5 mg fingolimod (FTY720) administered orally once daily in patients with relapsing forms of multiple sclerosis (CFTY720D2399- LONGTERMS)MS10029305multiple sclerosisNL-OMON47187ovartis95
进行中（未招募）
1 期
ong-term safety, tolerability and efficacy study of 0.5 mg fingolimod once daily in patients with multiple sclerosisEUCTR2010-020515-37-BEovartis Pharma Services AG5,000
进行中（未招募）
1 期
ong-term safety and tolerability of 0.5 mg fingolimod once daily in patients with relapsing forms of multiple sclerosismultiple sclerosisEUCTR2010-020515-37-GBovartis Pharma Services AG5,000